Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis
https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
150
150
Lysogene
https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinicTrial enrollment expected to begin…